logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
M

Mark J. Ratain

the university of chicago

88H-index
896Paper Count
3.8WCitation Count
Published Papers 192
Publication Date
logo
Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation
errClinical and Translational Science
IF2.8
err2026-04-08
err0
errOAAI
errThomas Chen; Amanda S. Andriessen; Matthew Jack; David George; Larry K. House; Clarence Chan; Kiang-Teck J. Yeo; Mark J. Ratain; Peter H. O'Donnell
errShare
errSave
Potential Alternative Dosage Strategies for Patent-Protected Oral Cancer Drugs
errEuropean Journal of Cancer
IF7.1
err2025-10-20
err0
PREAI
errAustin Wesevich; Liam J. Schmitt; Mark J. Ratain
errShare
errSave
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority
errcts clinical and translational science
IF0
err2025-08-26
err0
errOAAI
errMark J. Ratain; Garth W. Strohbehn
errShare
errSave
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients
errClinical Pharmacology & Therapeutics
IF5.5
err2025-08-22
err0
errOAAI
errZhong Huang; Kevin J. O'Leary; Edith A. Nutescu; Matthew Jack; Thomas Chen; Gregory W. Ruhnke; James C. Lee; David George; Larry K. House; Randall Knoebel; Luke V. Rasmussen; Seth Hartman; Anish Choksi; Kiang-Teck J. Yeo; Minoli A. Perera; Mark J. Ratain; David O. Meltzer; Peter H. O'Donnell
errShare
errSave
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes
errClinical Pharmacology & Therapeutics
IF5.5
err2025-06-27
err0
errOAAI
errYoungwoo Cho; Sami Elahi; Matthew M. Jack; John Campbell; Emily Smith; Randall W. Knoebel; David George; Larry House; Kiang-Teck J. Yeo; Theodore Karrison; Samuel L. Volchenboum; David O. Meltzer; Russell Z. Szmulewitz; Everett E. Vokes; Mark J. Ratain; Peter H. O'Donnell
errShare
errSave
Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
errClinical Pharmacology & Therapeutics
IF5.5
err2025-06-05
err0
PREAI
errWei Gao; Jiang Liu; Cynthia J. Musante; Hao Zhu; Matthew Thompson; Mirat Shah; Yanguang Cao; Vijay Ivaturi; Mark R. Conaway; Dean Bottino; Donghua Yin; Dorothee Semiond; Aram Oganesian; Mark J. Ratain; Chunze Li; Li Zhu; Ying C. Ou; Xiling Jiang; Jonathan Vallejo; Rajanikanth Madabushi; Qi Liu; Marc Theoret; Atiqur Rahman; Brian Booth; Olanrewaju Okusanya; Bernadette E. Johnson-Williams; Stacy S. Shord
errShare
errSave
Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing
errCTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
err2025-04-21
err0
errOAAI
errHuang, Zhong; Jack, Matthew; O'Leary, Kevin J.; Nutescu, Edith A.; Chen, Thomas; Ruhnke, Gregory W.; George, David; House, Larry K.; Knoebel, Randall; Hartman, Seth; Choksi, Anish; Yeo, Kiang-Teck J.; Perera, Minoli A.; Ratain, Mark J.; Meltzer, David O.; O'Donnell, Peter H.
errShare
errSave
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
errCOMMUNICATIONS MEDICINE
IF6.3
err2025-01-08
err0
errOAAI
errYazdani, Akram; Lenz, Heinz-Josef; Pillonetto, Gianluigi; Mendez-Giraldez, Raul; Yazdani, Azam; Sanoff, Hanna; Hadi, Reza; Samiei, Esmat; Venook, Alan P.; Ratain, Mark J.; Rashid, Naim; Vincent, Benjamin G.; Qu, Xueping; Wen, Yujia; Kosorok, Michael; Symmans, William F.; Shen, John Paul Y. C.; Lee, Michael S.; Kopetz, Scott; Nixon, Andrew B.; Bertagnolli, Monica M.; Perou, Charles M.; Innocenti, Federico
errShare
errSave
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2024-11-01
err0
PREAI
errPopat, Sanjay; Ratain, Mark J.
errShare
errSave
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)
errBMC GENOMICS
IF3.7
err2024-05-14
err0
errOAAI
errQuintanilha, Julia C. F.; Sibley, Alexander B.; Liu, Yingmiao; Niedzwiecki, Donna; Halabi, Susan; Rogers, Layne; O'Neil, Bert; Kindler, Hedy; Kelly, William; Venook, Alan; McLeod, Howard L.; Ratain, Mark J.; Nixon, Andrew B.; Innocenti, Federico; Owzar, Kouros
errShare
errSave
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2024-04-11
err4
errOAAI
errRatain, Mark J.
errShare
errSave
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders
errNATURE REVIEWS CLINICAL ONCOLOGY
IF82.2
err2024-01-30
err1
PREAI
errStrohbehn, Garth W.; Ratain, Mark J.
errShare
errSave
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States
errANNALS OF INTERNAL MEDICINE
IF15.2
err2024-01-01
err0
PREAI
errWesevich, Austin; Peek, Monica E.; Ratain, Mark J.
errShare
errSave
Special designations and the US Food and Drug Administration's dual mandate
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2023-12-07
err0
errOAAI
errStrohbehn, Garth W.; Ratain, Mark J.
errShare
errSave
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
errNATURE BIOTECHNOLOGY
IF41.7
err2023-11-10
err0
PREAI
errWesevich, Austin; Ratain, Mark J.
errShare
errSave
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2023-11-01
err0
PREAI
errRatain, Mark J.; Strohbehn, Garth W.
errShare
errSave
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
errBRITISH JOURNAL OF CANCER
IF6.8
err2023-08-04
err9
PREAI
errWesevich, Austin; Goldstein, Daniel A. A.; Paydary, Koosha; Peer, Cody J. J.; Figg, William D. D.; Ratain, Mark J. J.
errShare
errSave
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force COMMENT
errBLOOD ADVANCES
IF7.1
err2022-08-30
err5
errOAAI
errRatain, Mark J.; Tannock, Ian F.; Lichter, Allen S.
errShare
errSave
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
errINVESTIGATIONAL NEW DRUGS
IF2.7
err2022-04-25
err19
errOAAI
errLoRusso, Patricia; Ratain, Mark J.; Doi, Toshihiko; Rasco, Drew W.; de Jonge, Maja J. A.; Moreno, Victor; Carneiro, Benedito A.; Devriese, Lot A.; Petrich, Adam; Modi, Dimple; Morgan-Lappe, Susan; Nuthalapati, Silpa; Motwani, Monica; Dunbar, Martin; Glasgow, Jaimee; Medeiros, Bruno C.; Calvo, Emiliano
errShare
errSave
Lorlatinib Exposed: A Far From Optimal Dose
errCLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
err2022-04-08
err2
errOAAI
errStrohbehn, Garth W.; Ratain, Mark J.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
C
Charles M. Perou
H-index: 193 · Papers: 2.0K
D
David Cella
H-index: 184 · Papers: 1.9K
J
Jörge E. Cortes
H-index: 179 · Papers: 3.6K
E
Eric P. Winer
H-index: 170 · Papers: 1.6K
D
Drew M. Pardoll
H-index: 164 · Papers: 892
View more